Minireviews
Copyright ©The Author(s) 2021.
World J Gastroenterol. Nov 28, 2021; 27(44): 7661-7668
Published online Nov 28, 2021. doi: 10.3748/wjg.v27.i44.7661
Table 1 Published studies of Helicobacter pylori eradication therapy in patients allergic to penicillin
Ref.
Yr
Country
Study type
Treatment details
n
Success rate (PP, %)
Success rate (ITT, %)
Prach et al[10]1998United KingdomProspective,single cohort1st line O 20 mg b.d., C 500 mg t.d.s, 14 ds3100; 100;
Gisbert et al[11] 2005SpainProspective, single cohort1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line RBC 400 mg b.d., T 500 mg q.d.s., M 250 mg q.d.s., 7 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 ds 12; 17; 9; 264; 53; 17; 10058; 47; 11; 100
Rodriguez-Torres et al[12]2005Puerto RicoProspective, single cohort1st line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d; 2nd line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d17; 3NA; NA85; 100
Matsushima et al[13]2006JapanRetrospective, single cohort1st line PPI o.d., T 500 mg b.d., M 250 mg b.d., 7-14 d5100 80
Gisbert et al[14]2010SpainProspective, single cohort1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d50; 1555; 7354; 73
Tay et al[15]2012AustraliaProspective, single cohort2nd line R 20 mg t.d.s., B 240 mg q.d.s., RIF 150 mg b.d., CF 500 mg b.d., 10 d6994.2 94.2
Liang et al[16]2013ChinaProspective, randomised2nd line 109 pen allergic overall but results reported for whole group including non-allergic; L 30 mg b.d., B 220 mg b.d., T 500 mg t.d.s., F 100 mg t.d.s., 14 d; L 30 mg b.d., B 220 mg b.d., T 500 mg q.d.s., M 400 mg q.d.s., 14 d108; 10796.1; 93.1 91.7; 87.9
Furuta et al[17]2014JapanRetrospective, single cohort1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d7; 4; 9; 3; 3; 2100; 100; 100; 100; 100; 100 100; 100; 100; 100; 100; 100
Gisbert et al[18]2015SpainProspective, single cohort1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 4th line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 3rd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 1st line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d112; 24; 3; 2; 7; 2; 50; 3; 50; 1459; 38; 50; 0; 20; 100; 73; 100; 75; 64; 57; 37; 33; 50; 14; 100; 64; 100; 74; 64;
Mori et al[19]2017JapanProspective, single cohort1st line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 2nd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 3rd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d33; 19; 5100; 84.2; 40 100; 84.2; 40
Ono et al[20]2017JapanRetrospective,single cohort1st line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d10; 13; 20; 14; 3; 1; 24; 355.6; 92.3; 100; 100; 33.3; 100; 100; 66.750; 92.3; 100; 92.9; 33.3; 100; 100; 66.7
Sue et al[21]2017JapanProspective& retrospective, single cohort1st line V 20 mg b.d., C 200 or 400 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d, C 200 or 400 mg b.d, M 750 mg b.d., 7 d 20; 30100; 86.2 100; 83.3
Osumi et al[22]2017JapanProspective, single cohort1st line R 20 mg b.d, Mi 100 mg b.d, M 250 mg b.d., 7 d5100 100
Long et al[23]2018ChinaProspective, randomised1st line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st line E 20 mg b.d., B 600 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d33; 3370; 96 63.6; 84.8
Song et al[24]2019ChinaProspective, single cohort1st line E 20 mg b.d, B 220 mg b.d., LF 500 mg o.d., Cef 500 mg b.d., 14 d15290.1 85.5
Nyssen et al[25]2020EuropeRetrospective,multi-centre registry1st line PPI, C, M; 1st line PPI, C, LF; 1st line PPI, B, T, M; 2nd line PPI, C, LF; 2nd line PPI, M, LF; 2nd line PPI, B, T, M; 3rd line PPI, B, T, M; 3rd line PPI, B, C, LF; 3rd line PPI, C, LF (NB drug dose, frequency and duration not specified)285; 54; 250; 20; 13; 70; 18; 1; 269; 82; 92; 73.7; 76.5; 81.8; 77.8; 100; 50 69; 80; 91; 75; 76.5; 78.3; 77.8; 100; 50
Luo et al[26]2020ChinaProspective, single cohort1st & 2nd line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st & 2nd line E20 mg b.d., B 220 mg b.d., C 500 mg b.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., LF 500 mg o.d., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, LF 500 mg o.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., T 500 mg q.d.s., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, T 500 mg q.d.s., M 400 mg q.d.s., 14 d5; 22; 1; 10; 2; 72100; 94.1; 100; 100; 100; 100 100; 81.8; 100; 80; 100; 97.2
Sue et al[27]2021JapanProspective, single cohort2nd line V 20 mg b.d,, SF 100 mg b.d., M 250 mg b.d., 7 d1788.2 88.2